6311.0000 -59.00 (-0.93%)
NSE Sep 01, 2025 15:31 PM
Volume: 6,083
 

6311.00
-0.93%
IDBI Capital
Merck's Q2CY18 results were a mix bag. Topline was 27.2% below our estimates given the divestment in the business, however PAT was 7.6% above our estimates given better than expected EBITDA. Sales grew by 33.3% YoY to Rs2.2bn. EBITDA margins were at 23.1% up QoQ from 12% given higher gross margins and reduced OE. APAT was...
Procter & Gamble Health Ltd. is trading above all available SMAs
More from Procter & Gamble Health Ltd.
Recommended